{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:27Z","timestamp":1761128727116},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.gyobfe.2008.09.017","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T10:32:05Z","timestamp":1230201125000},"page":"50-56","source":"Crossref","is-referenced-by-count":3,"title":["Proposition d\u2019une strat\u00e9gie de pr\u00e9vention du risque fracturaire en d\u00e9but de m\u00e9nopause"],"prefix":"10.1016","volume":"37","author":[{"given":"F.","family":"Tr\u00e9mollieres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Pouilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ribot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gyobfe.2008.09.017_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene\u00a0: results from a 3-year randomized trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: results of the fracture intervention trial","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","article-title":"How long should patients take medications for postmenopausal osteoporosis?","volume":"74","author":"Briot","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archinte.164.10.1113","article-title":"An approach in identifying osteopenic women at increased short-term risk of fracture","volume":"164","author":"Miller","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib9","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture. The OFELY study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1359\/jbmr.020604","article-title":"Ten-year absolute risk of osteoporotic fractures according to BMD T\u00a0score at menopause: the Danish qsteoporosis prevention study","volume":"21","author":"Abrahamsen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib13","unstructured":"Traitement m\u00e9dicamenteux de l\u2019ost\u00e9oporose post-m\u00e9nopausique. Afssaps actualisation janvier 2006. http:\/\/agmed.sante.gouv.fr."},{"key":"10.1016\/j.gyobfe.2008.09.017_bib14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on the risk of fracture and bone mineral density. The women's health initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2007.03.019","article-title":"Transmenopausal changes in the trabecular bone structure","volume":"41","author":"Akhter","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1359\/jbmr.080108","article-title":"In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network following menopause and protective effect of estradiol","volume":"23","author":"Wehrli","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s001980170107","article-title":"Withdrawal of hormone replacement therapy is associated with vertebral bone loss in postmenopausal women","volume":"12","author":"Tr\u00e9mollieres","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-122-1-199501010-00002","article-title":"Estrogen replacement therapy and fractures in older women","volume":"122","author":"Cauley","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MOL.0b013e3282ef3bca","article-title":"Estrogens in vascular biology and disease: where do we stand today?","volume":"18","author":"Arnal","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential associations of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000113718","article-title":"The long-term effects of oophorectomy on cognitive and motor aging are age dependent","volume":"5","author":"Rocca","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.gme.0000191204.38664.61","article-title":"Hormone therapy, timing of initiation, and cognition in women aged older than 60\u00a0years: the REMEMBER pilot study","volume":"13","author":"MacLennan","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risk for breast cancer risk associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista\u00ae: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib27","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2\u00a0trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib28","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8\u00a0years: results from the continuing outcomes relevant to Evista\u00ae (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib34","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jc.87.8.3609","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib36","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.23461","article-title":"Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial","volume":"58","author":"Reginster","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1210\/jc.83.2.396","article-title":"Risedronate increases bone mass is early postmenopausal population: two years of treatement plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1\u00a0year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5\u00a0years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib40","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib43","first-page":"485","article-title":"Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate","volume":"13","author":"Cheung","year":"2007","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib44","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"10","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gyobfe.2008.09.017_bib45","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","article-title":"Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment","volume":"22","author":"Allen","year":"2007","journal-title":"J Bone Miner Res"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S129795890800458X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S129795890800458X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T10:50:11Z","timestamp":1545562211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S129795890800458X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S129795890800458X"],"URL":"https:\/\/doi.org\/10.1016\/j.gyobfe.2008.09.017","relation":{},"ISSN":["1297-9589"],"issn-type":[{"value":"1297-9589","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}